atoxbio.com Report : Visit Site

Technical data of the atoxbio.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host atoxbio.com. Currently, hosted in Israel and its service provider is Triple C Computation Ltd. .

the related websites

bbc.co.uk historicengland.org.uk meadowvaleprimary.co.uk careers.next.co.uk bgpa.wa.gov.au vickeryholman.com sportswise.org.uk dailymail.co.uk theump.co.uk gotorbay.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

home about us overview management team board of directors clinical advisors technology our platform publications pipeline pipeline overview nsti overview pre clinical data phase 2 phase 3 aki overview pre clinical data clinical data investors news press releases contact search menu this is atox bio atox bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. reltecimod (ab103) , the company’s lead product, is studied in accute (reltecimod clinical composite endpoint study in necrotizing soft tissue infections), a phase 3 clinical trial in patients with necrotizing soft tissue infections, a rare, life threatening infection for which no therapy currently exists. reltecimod is also studied in reakt (reltecimod efficacy for acute kidney injury trial), a phase 2 study in patients with abdominal sepsis induced acute kidney injury. reltecimod received orphan drug designation from the fda and ema and fast track designation from the fda. learn more call us this is atox bio atox bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. reltecimod (ab103) , the company’s lead product, is studied in accute (reltecimod clinical composite endpoint study in necrotizing soft tissue infections), a phase 3 clinical trial in patients with necrotizing soft tissue infections, a rare, life threatening infection for which no therapy currently exists. reltecimod is also studied in reakt (reltecimod efficacy for acute kidney injury trial), a phase 2 study in patients with abdominal sepsis induced acute kidney injury. reltecimod received orphan drug designation from the fda and ema and fast track designation from the fda. learn more call us this is atox bio atox bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. reltecimod (ab103) , the company’s lead product, is studied in accute (reltecimod clinical composite endpoint study in necrotizing soft tissue infections), a phase 3 clinical trial in patients with necrotizing soft tissue infections, a rare, life threatening infection for which no therapy currently exists. reltecimod is also studied in reakt (reltecimod efficacy for acute kidney injury trial), a phase 2 study in patients with abdominal sepsis induced acute kidney injury. reltecimod received orphan drug designation from the fda and ema and fast track designation from the fda. learn more call us previous next 1 2 3 our purpose is to improve outcomes by developing therapies for serious, unmet medical conditions in the critical care setting where no, or limited, therapies are available. learn more about us established in 2003, atox bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients. our focus is on acute, life threatening, conditions resulting from a severe acute inflammation caused by severe infections. read more… technology short peptide immunomodulators capable of attenuating, but not inhibiting, excessive severe acute inflammation, commonly the cause of pathology and organ failure in severe infectious diseases. the peptides bind to a unique domain on cd28, a co-stimulatory receptor, affecting downstream. read more… pipeline reltecimod is being studied in accute, a phase 3 clinical trial in patients with necrotizing soft tissue infections. a phase 2 study is planned in patients with aki. additional indications are currently in pre-clinical studies. …read more israel office 8 pinhas sapir st. weizmann science park ness ziona, 7403631 israel po box 2318, rehovot 7612202 tel: +972-8-648-4111 fax: +972-8-648-4555 us office 55 vilcom center drive suite 230 chapel hill, nc 27514 usa tel: + 1-919-636-7260 © copyright - | design by: portnov mishan | site by: foothold systems scroll to top

URL analysis for atoxbio.com

http://www.atoxbio.com/about-us/overview/
http://www.atoxbio.com/pipeline/aki/animal-data/
http://www.atoxbio.com/pipeline/nsti/animal-data/
http://www.atoxbio.com/#2
http://www.atoxbio.com/#1
http://www.atoxbio.com/about-us/board-of-directors/
http://www.atoxbio.com/pipeline/nsti/overview/
http://www.atoxbio.com/technology/our-platform/
http://www.atoxbio.com/#next
http://www.atoxbio.com/pipeline/aki/overview/
http://www.atoxbio.com/about-us/
http://www.atoxbio.com/#prev
http://www.atoxbio.com/#3
http://www.atoxbio.com/#top
http://www.atoxbio.com/technology/publications/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: ATOXBIO.COM
Registry Domain ID: 103537678_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.domainthenet.com
Registrar URL: http://www.DomainTheNet.com
Updated Date: 2015-09-03T07:55:56Z
Creation Date: 2003-09-14T12:12:37Z
Registry Expiry Date: 2018-09-14T12:12:37Z
Registrar: Domain The Net Technologies Ltd.
Registrar IANA ID: 10007
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: 972-3-7600500
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.DTNT.INFO
Name Server: NS2.DTNT.INFO
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-13T09:45:05Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Domain The Net Technologies Ltd.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =atoxbio.com

  PORT 43

  TYPE domain

DOMAIN

  NAME atoxbio.com

  CHANGED 2015-09-03

  CREATED 2003-09-14

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS1.DTNT.INFO 62.219.91.139

  NS2.DTNT.INFO 62.219.91.150

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .